Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
The National Eye Institute (NEI), part of the National Institutes of Health (NIH), announces the release of more than 10 years of data collected during the Age-Related Eye Disease Study (AREDS).
Three young adults with Leber Congenital Amaurosis-a severe degenerative disease of the retina caused by a mutation in the RPE65 gene-reported improvements in vision after undergoing a specialized gene transfer procedure.
A promising new drug therapy used to treat abnormal swelling in the eye-a condition called diabetic macular edema-proved less effective than traditional laser treatments in a study funded by the National Eye Institute (NEI), part of the NIH.
Investigators reported in 1993 that the progressive course of retinal degeneration, as assessed by the electroretinogram (ERG), was slower on average among adults with retinitis pigmentosa.
Two groups of investigators have reported independently on their initial observations from Phase I clinical trials of gene transfer for Leber congenital amaurosis (LCA) caused by mutations in the RPE65 gene.
The age pool of corneas for transplant should be expanded to include donors up to 75 years of age, based on findings from a study funded by the National Eye Institute (NEI), one of the National Institutes of Health.
The National Eye Institute (NEI) of the National Institutes of Health (NIH) announces the start of a multicenter clinical trial to compare the relative safety and effectiveness of two drugs currently used to treat advanced age-related macular degeneration
The National Eye Institute (NEI) of the National Institutes of Health (NIH) is supporting a phase I clinical trial to assess the safety of gene transfer in treating people with a form of Leber congenital amaurosis (LCA).